Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Dow Jones11-27

By Stephen Nakrosis

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

Acadia said it initially plans to develop SAN711 for essential tremor, a neurological condition that includes shaking or trembling in the body. The company said it plans to initiate a Phase 2 study of SAN711 in essential tremor in 2026.

Under the terms of the, Saniona would receive an upfront payment of $28 million, with potential milestone payments of up to $582 million. Saniona is eligible to receive tiered royalties of up to $435 million, Acadia said.

Catherine Owen Adams, Acadia's chief executive officer, said essential tremor is a condition that has not seen innovation in treatment for decades.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 26, 2024 18:07 ET (23:07 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486485686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 07:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486485686","market":"sg","top_or_hot":-1,"title":"Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711. \n</p>\n<p>\n  Acadia said it initially plans to develop SAN711 for essential tremor, a neurological condition that includes shaking or trembling in the body. The company said it plans to initiate a Phase 2 study of SAN711 in essential tremor in 2026. \n</p>\n<p>\n  Under the terms of the, Saniona would receive an upfront payment of $28 million, with potential milestone payments of up to $582 million. Saniona is eligible to receive tiered royalties of up to $435 million, Acadia said. \n</p>\n<p>\n  Catherine Owen Adams, Acadia's chief executive officer, said essential tremor is a condition that has not seen innovation in treatment for decades. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 26, 2024 18:07 ET (23:07 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 07:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Stephen Nakrosis \n\n\n \n\n\n  Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711. \n\n\n  Acadia said it ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065171311.SGD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2486485686","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486485686","pubTimestamp":1732662420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.Acadia said it initially plans to develop SAN711 for essential tremor, a neurological condition that includes shaking or trembling in the body. The company said it plans to initiate a Phase 2 study of SAN711 in essential tremor in 2026.Under the terms of the, Saniona would receive an upfront payment of $28 million, with potential milestone payments of up to $582 million. Saniona is eligible to receive tiered royalties of up to $435 million, Acadia said.Catherine Owen Adams, Acadia's chief executive officer, said essential tremor is a condition that has not seen innovation in treatment for decades.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","ACAD":"阿卡迪亚","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4080":"零售业房地产投资信托","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4231":"零售房地产信托","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","AKR":"阿卡迪亚房地产信托"},"translate_title":"Acadia Pharmaceuticals与Saniona签订SAN711独家许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1,"ACAD":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711. \n\n\n  Acadia said it initially plans to develop SAN711 for essential tremor, a neurological condition that includes shaking or trembling in the body. The company said it plans to initiate a Phase 2 study of SAN711 in essential tremor in 2026. \n\n\n  Under the terms of the, Saniona would receive an upfront payment of $28 million, with potential milestone payments of up to $582 million. Saniona is eligible to receive tiered royalties of up to $435 million, Acadia said. \n\n\n  Catherine Owen Adams, Acadia's chief executive officer, said essential tremor is a condition that has not seen innovation in treatment for decades. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 26, 2024 18:07 ET (23:07 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486485686"}